Provided by Tiger Fintech (Singapore) Pte. Ltd.

ASCENTAGE-B

83.850
+0.2500.30%
Volume:4.20M
Turnover:351.74M
Market Cap:31.19B
PE:-57.18
High:85.800
Open:84.300
Low:81.300
Close:83.600
Loading ...

Ascentage Pharma Group International Announces Regulatory Review for Lisaftoclax in China Following New Drug Application Submission

Reuters
·
23 May

Ascentage Pharma Group International Conducted Annual General Meeting

Reuters
·
19 May

Ascentage Pharma Presents Results of Five Preclinical Studies for Anti-Cancer Drugs

MT Newswires Live
·
29 Apr

Ascentage Pharma Trustee Buys HK$1.8 Million Shares

MT Newswires Live
·
09 Apr

SPDB International HK Starts Ascentage Pharma Group International at Buy with HK$57 Price Target

MT Newswires Live
·
03 Apr

Ascentage Pharma Group International Full Year 2024 Earnings: Misses Expectations

Simply Wall St.
·
29 Mar

Ascentage Pharma Narrows Loss in 2024

MT Newswires Live
·
28 Mar

BRIEF-Ascentage Pharma Group International Says Revenue In 2024 Increased 342% Year-Over-Year

Reuters
·
27 Mar

BRIEF-Ascentage Pharma Reports Full Year 2024 Unaudited Financial Results And Business Updates

Reuters
·
27 Mar

Press Release: Ascentage Pharma Reports Full Year 2024 Unaudited Financial Results and Business Updates

Dow Jones
·
27 Mar

China Designates Ascentage's Olverembatinib Cancer Therapy as Breakthrough Therapy

MT Newswires Live
·
06 Mar

BRIEF-Ascentage Pharma Group International Says Olverembatinib Given Breakthrough Therapy Designation

Reuters
·
06 Mar

BRIEF-Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Reuters
·
06 Mar

Retail investors are Ascentage Pharma Group International's (HKG:6855) biggest owners and were hit after market cap dropped HK$720m

Simply Wall St.
·
05 Mar